According to NASL 2010, less than 20% of surveyed patients felt their nasal allergies were completely controlled over a one week time period.
The vast majority of allergists, otolaryngologists and primary care providers interviewed in the survey stated intranasal corticosteroid sprays as their preferred treatment of choice for adults with moderate to severe persistent nasal allergies.
Among the patients surveyed in NASL 2010 who were familiar with intranasal corticosteroid sprays, nearly four times as many say that the benefits of these medications outweigh the drawbacks.
However, survey results found that nasal allergy patients who have used an intranasal corticosteroid spray in the last year report dripping down the throat as a moderately or extremely bothersome side effect.
Gary Gross of FAAAAI Dallas Allergy & Asthma Center said the NASL survey results further support the need for more effective treatment options that address these specific issues for patients living with allergic rhinitis.
"When patients experience symptoms of nasal allergies it can impact their work performance by reducing productivity, which leads to both social and economic costs," Gross said.
"Until there are products that alleviate bothersome symptoms like post-nasal drip, we’ll continue to see dissatisfaction and low treatment compliance among patients. It’s important for patients to maintain adherence with their medications to manage symptoms and achieve better outcomes."
Teva Respiratory is the US based respiratory subsidiary of Teva Pharmaceutical Industries.